Literature DB >> 16778565

The role of cholesterol in prostate cancer.

Martin H Hager1, Keith R Solomon, Michael R Freeman.   

Abstract

PURPOSE OF REVIEW: Experimental and epidemiological evidence suggests that cholesterol may play a promotional role in prostate cancer development and progression. This review seeks to provide an overview of established links between cholesterol and prostate cancer, with an emphasis on very recent scientific contributions supporting a role of cholesterol in prostate cancer etiology. RECENT
FINDINGS: Elevated cholesterol levels in prostate cancer cells have been found to result from aberrant regulation of cholesterol metabolism. Recent studies have identified Akt/protein kinase B and sterol response element binding proteins as major players regulating cholesterol biosynthesis and feedback regulation. It has also become apparent that prostate cancer cells process critical cell survival cues via specialized membrane microdomains that are dependent on cholesterol for signal transduction. These findings converge to support a scenario in which abnormal cholesterol metabolism influences signal transduction events at the membrane in a manner that promotes tumor cell growth, inhibits apoptotic signals and potentially stimulates other malignant cellular behaviors.
SUMMARY: Recent experimental evidence has invigorated the discussion of a role for cholesterol in prostate cancer. The identification of cholesterol as a critical component in signal transduction events in prostate cancer cells has not only provided new mechanistic insights but also opened up new avenues for chemotherapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778565     DOI: 10.1097/01.mco.0000232896.66791.62

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  58 in total

1.  Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.

Authors:  J A Gordon; A Midha; A Szeitz; M Ghaffari; H H Adomat; Y Guo; T L Klassen; E S Guns; K M Wasan; M E Cox
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-04       Impact factor: 5.554

Review 2.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

3.  An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Authors:  Deliang Guo; Felicia Reinitz; Mary Youssef; Cynthia Hong; David Nathanson; David Akhavan; Daisuke Kuga; Ali Nael Amzajerdi; Horacio Soto; Shaojun Zhu; Ivan Babic; Kazuhiro Tanaka; Julie Dang; Akio Iwanami; Beatrice Gini; Jason Dejesus; Dominique D Lisiero; Tiffany T Huang; Robert M Prins; Patrick Y Wen; H Ian Robins; Michael D Prados; Lisa M Deangelis; Ingo K Mellinghoff; Minesh P Mehta; C David James; Arnab Chakravarti; Timothy F Cloughesy; Peter Tontonoz; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-15       Impact factor: 39.397

4.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Authors:  Shuhua Yue; Junjie Li; Seung-Young Lee; Hyeon Jeong Lee; Tian Shao; Bing Song; Liang Cheng; Timothy A Masterson; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

5.  Androgen deprivation by activating the liver X receptor.

Authors:  Jung Hoon Lee; Haibiao Gong; Shaheen Khadem; Yi Lu; Xiang Gao; Song Li; Jian Zhang; Wen Xie
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

6.  Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study.

Authors:  Rishikesh Mankidy; Pearson Wk Ahiahonu; Hong Ma; Dushmanthi Jayasinghe; Shawn A Ritchie; Mohamed A Khan; Khine K Su-Myat; Paul L Wood; Dayan B Goodenowe
Journal:  Lipids Health Dis       Date:  2010-06-14       Impact factor: 3.876

Review 7.  Rationale for statins in the chemoprevention of prostate cancer.

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

8.  PPARδ promotes oncogenic redirection of TGF-β1 signaling through the activation of the ABCA1-Cav1 pathway.

Authors:  Nam-Gu Her; Seong-In Jeong; Kyucheol Cho; Tae-Kyu Ha; Jikhyon Han; Kyung-Phil Ko; Soon-Ki Park; Jin-Hee Lee; Min-Goo Lee; Byung-Kyu Ryu; Sung-Gil Chi
Journal:  Cell Cycle       Date:  2013-04-17       Impact factor: 4.534

Review 9.  The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.

Authors:  Laura M Deford-Watts; Akiva Mintz; Steven J Kridel
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.

Authors:  Wendy Demark-Wahnefried; Stephen L George; Boyd R Switzer; Denise C Snyder; John F Madden; Thomas J Polascik; Mack T Ruffin; Robin T Vollmer
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.